Evidence map›Paper›PMID 41167699›Full record

ArticleIn vivo (Athens, Greece)

The Prognostic Impact of HER2 Status and Survival Outcomes in Metastatic Triple Negative Breast Cancer.

Alper Turkel, Ece Baydar, Rümeysa Çolak, Ahmet Emin Öztürk, Teoman Şakalar, Sinem Akbaş, Hasibe Bilge Gür, Eyyüp Çavdar, Mesut Yilmaz, Devrim Çabuk and 3 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alper TurkelDepartment of Medical Oncology, University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Treatment Hospital, Ankara, Türkiye; turkelalperr@gmail.com.
Ece BaydarDepartment of Medical Oncology, Kocaeli University, Faculty of Medicine, Kocaeli, Türkiye.
Rümeysa ÇolakDepartment of Medical Oncology, Bakırköy Dr. Sadi Konuk Research and Treatment Hospital, Istanbul, Türkiye.
Ahmet Emin ÖztürkDepartment of Medical Oncology, University of Health Sciences, Prof. Dr. Cemil Taşçıoğlu City Hospital, Istanbul, Türkiye.
Teoman ŞakalarDepartment of Medical Oncology, Kahramanmaraş Sütçü İmam University, Faculty of Medicine, Kahramanmaraş, Türkiye.
Sinem AkbaşDepartment of Medical Oncology, Koç University, Faculty of Medicine, Istanbul, Türkiye.
Hasibe Bilge GürDepartment of Medical Oncology, Sakarya Research and Treatment Hospital, Sakarya, Türkiye.
Eyyüp ÇavdarDepartment of Medical Oncology, Adıyaman University Research and Treatment Hospital, Adiyaman, Türkiye.
Mesut YilmazDepartment of Medical Oncology, Bakırköy Dr. Sadi Konuk Research and Treatment Hospital, Istanbul, Türkiye.
Devrim ÇabukDepartment of Medical Oncology, Kocaeli University, Faculty of Medicine, Kocaeli, Türkiye.
Fatih SelçukbiricikDepartment of Medical Oncology, Koç University, Faculty of Medicine, Istanbul, Türkiye.
Ilhan HacibekiroğluDepartment of Medical Oncology, Sakarya Research and Treatment Hospital, Sakarya, Türkiye.
Mutlu DoganDepartment of Medical Oncology, University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Treatment Hospital, Ankara, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThis study investigated the prognostic impact of human epidermal growth factor-2 receptor (HER2) status on the survival of patients with metastatic triple-negative breast cancer (TNBC). PATIENTS AND

methodsThis multicenter, retrospective study included 168 patients diagnosed with recurrent or

resultsThe median follow-up was 44 months [95% confidence interval (CI)=35.7-52.2]. All patients received systemic chemotherapy as part of their first-line treatment. The median progression-free survival (PFS) in all patients was 9 months (95%CI=7.7-10.3 months). The median overall survival (OS) in all patients was 22 months (95%CI=17.4-26.5 months). Higher Ki67 value at diagnosis was a significant poor prognostic factor for median OS (29 months

conclusionHER2-low expression was associated with significantly improved survival compared with HER2-negative status in metastatic TNBC. These findings highlight HER2 status as a potential prognostic factor, particularly relevant in settings with limited access to novel therapies such as immunotherapy or antibody-drug conjugates.

Indexed as

Biomarkers, TumorErb-b2 Receptor Tyrosine KinasesTriple Negative Breast NeoplasmsAdultAgedAged, 80 and overFemaleHumansMiddle AgedPrognosisRetrospective StudiesBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesHER2-lowHER2 statusMetastaticsurvivaltriple-negative breast cancer

Identifiers

PMID41167699
PMCPMC12588230

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.